Suzanne Kamel-Reid mainly focuses on Internal medicine, Oncology, Cancer research, Cancer and Carcinoma. Her work deals with themes such as Surgery and Immunology, which intersect with Internal medicine. Her Oncology research is multidisciplinary, incorporating perspectives in Clinical trial and Epidermal growth factor receptor.
Her work on Imatinib mesylate as part of general Cancer research study is frequently linked to Hydroxymethylglutaryl-CoA reductase, bridging the gap between disciplines. Her Erlotinib research incorporates elements of KRAS, Survival analysis and Hazard ratio. Her research integrates issues of EGFR Gene Amplification and Adenocarcinoma in her study of Erlotinib Hydrochloride.
Suzanne Kamel-Reid focuses on Internal medicine, Oncology, Cancer research, Pathology and Cancer. Her work in Internal medicine addresses subjects such as Gastroenterology, which are connected to disciplines such as Surgery. The various areas that Suzanne Kamel-Reid examines in her Oncology study include Immunology, Bioinformatics and Hazard ratio.
She has included themes like Haematopoiesis, Stem cell and NPM1 in her Immunology study. In her work, Retinoic acid receptor alpha and Molecular biology is strongly intertwined with Acute promyelocytic leukemia, which is a subfield of Cancer research. Erlotinib is a subfield of Epidermal growth factor receptor that Suzanne Kamel-Reid studies.
Internal medicine, Oncology, DNA sequencing, KRAS and Lung cancer are her primary areas of study. Her Oncology study combines topics in areas such as Cancer, Metastasis, Germline mutation and Hazard ratio. Her studies in DNA sequencing integrate themes in fields like Bioinformatics, Myeloid, Standard of care, Genomic sequencing and Computational biology.
Her KRAS study incorporates themes from Serous fluid and Adenocarcinoma. Her work in the fields of Lung cancer, such as Non small cell, intersects with other areas such as Context. Her DNA profiling research is multidisciplinary, incorporating elements of Cancer research and Immunology.
Her main research concerns Internal medicine, Oncology, DNA sequencing, KRAS and Pathology. In the field of Internal medicine, her study on Radiation therapy, Clinical trial and Hazard ratio overlaps with subjects such as Laboratory Proficiency Testing and In patient. Suzanne Kamel-Reid works in the field of Oncology, namely Lung cancer.
Her research in DNA sequencing intersects with topics in Molecular pathology, Computational biology, MEDLINE and Bioinformatics. The concepts of her Pathology study are interwoven with issues in Polymerase chain reaction and In situ hybridization. The study incorporates disciplines such as Liquid biopsy and Cancer research in addition to Immunology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Ming Sound Tsao;Akira Sakurada;Jean Claude Cutz;Jean Claude Cutz;Chang Qi Zhu;Chang Qi Zhu.
The New England Journal of Medicine (2005)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy P Hughes;Michael W Deininger;Andreas Hochhaus;Susan Branford.
Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
Chang Qi Zhu;Gilda Da Cunha Santos;Keyue Ding;Akira Sakurada.
Journal of Clinical Oncology (2008)
Engraftment of immune-deficient mice with human hematopoietic stem cells
Suzanne Kamel-Reid;John E. Dick.
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Susan Branford;Linda Fletcher;Nicholas C.P. Cross;Martin C. Müller.
Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.
Lawrence J. Jennings;Maria E. Arcila;Christopher Corless;Suzanne Kamel-Reid;Suzanne Kamel-Reid.
The Journal of Molecular Diagnostics (2017)
Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group
Amit M. Oza;Laurie Elit;Ming-Sound Tsao;Suzanne Kamel-Reid.
Journal of Clinical Oncology (2011)
Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia.
Richard A. Wells;Charles Catzavelos;Suzanne Kamel-Reid;Suzanne Kamel-Reid.
Nature Genetics (1997)
A model of human acute lymphoblastic leukemia in immune-deficient SCID mice
Suzanne Kamel-Reid;Michelle Letarte;Christian Sirard;Monica Doedens.
Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma
Nilva K. Cervigne;Patricia P. Reis;Jerry Machado;Bekim Sadikovic.
Human Molecular Genetics (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: